5 Minutes with Dr Louise Jackett
27 April 2016
To educate the next generation of melanoma researchers and doctors, MIA offers a number of unique clinical and research-based Fellowships each year. They are made possible thanks to the generosity of our donors.
Dr Louise Jackett is our 2016 Jani Haenke Melanoma Pathology Fellow.
Why did you apply for our Fellowship program?
I was drawn to the Melanoma Pathology Fellowship at MIA for the chance to work with a team at the forefront of melanoma research. Also, the diagnosis of melanoma and other melanocytic lesions under the microscope can be very difficult and this role allows me to learn from the best.
Tell us about your role with MIA?
I combine research activities and reporting of melanoma cases. Many of these cases are for patients treated at MIA but some are difficult cases that have come from pathologists nation-wide or internationally for expert opinion and I find these challenging and very interesting.
What drives you to come to work each day?
I find huge value in providing important information about patients’ health conditions. I also stay mindful of the generous donors who make my position possible.
Where did you work before coming to MIA?
I undertook my primary medical degree (MBBS, BMedSci) at the University of Tasmania and moved to Melbourne when I was a resident medical officer. There I pursued my anatomical pathology training over 5 years and recently gained fellowship with the Royal College of Pathologists of Australasia.
What are you hoping to achieve through your Fellowship at MIA?
I am hoping to increase my expertise in the tricky aspects of melanoma diagnosis, such as atypical melanocytic lesions and their distinction from melanoma. During the year I hope to publish on several projects that I am personally driving, as well as collaborating with many other MIA researchers by providing a pathological viewpoint and expertise.
What do you like to do in your spare time?
I like to counteract my sedentary microscope work by being very active! I love running, cycling and yoga.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.